TERN

Terns Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website ernspharma.com
Employees(FY) 46
ISIN US8808811074

Performance

-11.08%

-0.85%

-41.63%

-20.49%

-9.71%

YTD

-6.84%

Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Advanced Technical Analysis

Technical Analysis of TERN 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TERN

Stock Rank

Recent News & Updates

2024-12-16 13:10
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?(Insider Monkey)
2024-12-11 05:30
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock(Simply Wall St.)
2024-12-04 09:09
Oppenheimer Adjusts Price Target on Terns Pharmaceuticals to $20 From $17, Keeps Outperform Rating(MT Newswires)
2024-12-03 07:00
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia(GlobeNewswire)
2024-12-02 18:00
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia(Globenewswire)
2024-12-02 16:05
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)(GlobeNewswire)
2024-12-02 03:05
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)(Globenewswire)
2024-11-18 16:05
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors(GlobeNewswire)
2024-11-18 03:05
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors(Globenewswire)
2024-11-14 05:17
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth(Simply Wall St.)
2024-11-12 16:05
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates(GlobeNewswire)
2024-11-12 03:05
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates(Globenewswire)
2024-11-06 16:05
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences(GlobeNewswire)
2024-10-31 09:00
Oppenheimer Initiates Terns Pharmaceuticals at Outperform With $17 Price Target(MT Newswires)
2024-10-07 16:05
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)(GlobeNewswire)
2024-10-07 04:05
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)(Globenewswire)
2024-09-30 07:27
Mizuho Raises Price Target on Terns Pharmaceuticals to $14 From $10, Keeps Outperform Rating(MT Newswires)
2024-09-24 03:22
Insiders Snap Up These 2 ‘Strong Buy’ Stocks(TipRanks)
2024-09-18 10:07
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments(Motley Fool)
2024-09-17 01:30
OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc(GuruFocus.com)
2024-09-16 10:14
With 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backing(Simply Wall St.)
2024-09-15 07:21
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.(Motley Fool)
2024-09-15 06:09
Should You Invest in This Under-the-Radar Weight Loss Stock?(Motley Fool)
2024-09-14 10:12
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More(Motley Fool)
2024-09-12 19:00
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares(GlobeNewswire)
2024-09-12 12:49
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More(Zacks)
2024-09-12 07:00
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares(Globenewswire)
2024-09-11 03:56
Terns Pharmaceuticals Prices $150.2 Million Public Offering(MT Newswires)
2024-09-10 22:50
Terns Announces Pricing of Upsized $150.15 Million Public Offering(GlobeNewswire)
2024-09-10 11:29
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug(Zacks)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.